<DOC>
	<DOC>NCT01468558</DOC>
	<brief_summary>Compare the DHE pharmacokinetic profiles observed following administration of: 1. MAP0004 (oral inhalation DHE) 2. MAP0004 co-administered with oral Ketoconazole 3. Intravenous (IV) DHE (D.H.E.45Â®, the approved reference therapy) Compare the tolerability of MAP0004, IV DHE, and MAP0004 with co-administration of Ketoconazole.</brief_summary>
	<brief_title>Pharmacokinetics &amp; Tolerability Study of MAP0004 Co-administered With Ketoconazole</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Dihydroergotamine</mesh_term>
	<criteria>Major Able to provide written Informed Consent Male or Female subjects 18 to 45 years old Female subjects who are practicing adequate contraception or who are sterile Stable cardiac status Normal rhythm or arrhythmia deemed clinically insignificant on ECG Contraindication to dihydroergotamine mesylate (DHE) Use of any excluded concomitant medications within the 10 days prior to Visit 1 History of hemiplegic or basilar migraine Participation in another investigational trial during the 12 weeks prior to Visit 1 or during this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Drug Drug Interaction Study in Normal Healthy Volunteers</keyword>
</DOC>